Intermediate-Dose Cytarabine as Postinduction AML Therapy

Mathilde Hunault, Cécile Pautas, Sarah Bertoli, Pierre-Yves Dumas, Emmanuel Raffoux, Marie-Anne Hospital, Tony Marchand, Maël Heiblig, Sylvain Chantepie, Martin Carré, Pierre Peterlin, Maria-Pilar Gallego-Hernanz, Emilie Lemasle, Romain Guièze, Célestine Simand, Pascal Turlure, Anne Huynh, Thibaut Leguay, Raynier Devillier, Stéphanie Nguyen Quoc, Nicolas Duployez, Isabelle Luquet, Dominique Penther, Karine Celli-Lebras, Ariane Mineur, Nicole Raus, Claude Gardin, Gérard Socié, Jean-Yves Cahn, Norbert Ifrah, Norbert Vey, Régis Peffault de Latour, Eric Delabesse, Claude Preudhomme, Jean-François Hamel, Arnaud Pigneux, Christian Récher, Hervé Dombret

Open source

DOI: 10.1056/evidoa2400326
Published: 2025-06-24
Container: NEJM Evidence
Publisher: Massachusetts Medical Society
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/evidoa2400326,
  title = {Intermediate-Dose Cytarabine as Postinduction AML Therapy},
  author = {Mathilde Hunault and Cécile Pautas and Sarah Bertoli and Pierre-Yves Dumas and Emmanuel Raffoux and Marie-Anne Hospital and Tony Marchand and Maël Heiblig and Sylvain Chantepie and Martin Carré and Pierre Peterlin and Maria-Pilar Gallego-Hernanz and Emilie Lemasle and Romain Guièze and Célestine Simand and Pascal Turlure and Anne Huynh and Thibaut Leguay and Raynier Devillier and Stéphanie Nguyen Quoc and Nicolas Duployez and Isabelle Luquet and Dominique Penther and Karine Celli-Lebras and Ariane Mineur and Nicole Raus and Claude Gardin and Gérard Socié and Jean-Yves Cahn and Norbert Ifrah and Norbert Vey and Régis Peffault de Latour and Eric Delabesse and Claude Preudhomme and Jean-François Hamel and Arnaud Pigneux and Christian Récher and Hervé Dombret},
  year = {2025},
  journal = {NEJM Evidence},
  doi = {10.1056/evidoa2400326},
  url = {https://doi.org/10.1056/evidoa2400326}
}

RIS

TY  - JOUR
TI  - Intermediate-Dose Cytarabine as Postinduction AML Therapy
AU  - Mathilde Hunault
AU  - Cécile Pautas
AU  - Sarah Bertoli
AU  - Pierre-Yves Dumas
AU  - Emmanuel Raffoux
AU  - Marie-Anne Hospital
AU  - Tony Marchand
AU  - Maël Heiblig
AU  - Sylvain Chantepie
AU  - Martin Carré
AU  - Pierre Peterlin
AU  - Maria-Pilar Gallego-Hernanz
AU  - Emilie Lemasle
AU  - Romain Guièze
AU  - Célestine Simand
AU  - Pascal Turlure
AU  - Anne Huynh
AU  - Thibaut Leguay
AU  - Raynier Devillier
AU  - Stéphanie Nguyen Quoc
AU  - Nicolas Duployez
AU  - Isabelle Luquet
AU  - Dominique Penther
AU  - Karine Celli-Lebras
AU  - Ariane Mineur
AU  - Nicole Raus
AU  - Claude Gardin
AU  - Gérard Socié
AU  - Jean-Yves Cahn
AU  - Norbert Ifrah
AU  - Norbert Vey
AU  - Régis Peffault de Latour
AU  - Eric Delabesse
AU  - Claude Preudhomme
AU  - Jean-François Hamel
AU  - Arnaud Pigneux
AU  - Christian Récher
AU  - Hervé Dombret
PY  - 2025
JO  - NEJM Evidence
DO  - 10.1056/evidoa2400326
UR  - https://doi.org/10.1056/evidoa2400326
ER  -

APA

Hunault, M., Pautas, C., Bertoli, S., Dumas, P., Raffoux, E., Hospital, M., Marchand, T., Heiblig, M., Chantepie, S., Carré, M., Peterlin, P., Gallego-Hernanz, M., Lemasle, E., Guièze, R., Simand, C., Turlure, P., Huynh, A., Leguay, T., Devillier, R., Quoc, S. N., Duployez, N., Luquet, I., Penther, D., Celli-Lebras, K., Mineur, A., Raus, N., Gardin, C., Socié, G., Cahn, J., Ifrah, N., Vey, N., Latour, R. P. D., Delabesse, E., Preudhomme, C., Hamel, J., Pigneux, A., Récher, C., & Dombret, H. (2025). Intermediate-Dose Cytarabine as Postinduction AML Therapy. NEJM Evidence. https://doi.org/10.1056/evidoa2400326

Source records

crossref · retrieved 2026-09-25T16:27:25.001Z